FindTrial
Sign In

The decreasing effect of rose hip-derived tiliroside on the abdominal visceral fat - A systematic review

The decreasing effect of rose hip-derived tiliroside on the abdominal visceral fat - A systematic review - A systematic review of rose hip-derived tiliroside

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000030442
Enrollment
1
Registered
2017-12-18
Start date
2017-12-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult volunteers

Interventions

None listed

Sponsors

Morishita Jintan Co., Ltd.
Lead Sponsor
Review team Dr. Yukimasa Tanaka, Health Care Product Department, Morishita Jintan Co., Ltd. Mr. Akifumi Nagatomo, Health Care Product Department, Morishita Jintan Co., Ltd. Ms. Ai Matsumoto, Health Care Product Department, Morishita Jintan Co., Ltd. Ms. Yuki Yoshimoto, Health Care Product Department, Morishita Jintan Co., Ltd. Ms. Maho Oguri, Health Care Product Department, Morishita Jintan Co., Ltd. Research collaborator Professor Hiroharu Kamioka, Faculty of Regional Environment Scien
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (PICOS) Participant: Healthy adults. Minors, pregnant women, and lactating women will be excluded. Intervention: Ingestion of food containing more than 0.1 mg of rose hip-derived tiliroside. Comparison: Ingestion of food not containing rose hip-derived tiliroside. Outcome: Abdominal visceral fat area. Study design: Randomized parallel-group controlled trials, randomized crossover trials, quasi randomized controlled trials, and non-randomized controlled trials will be included. Eligibility is not restricted by language. Proceedings and unpublished studies will be excluded. The scientific papers and reports which give us enough research details will be included.

Exclusion criteria

Exclusion criteria: The literature which does not meet the key inclusion criteria will be excluded.

Design outcomes

Primary

MeasureTime frame
Abdominal visceral fat area—

Secondary

MeasureTime frame
Abdominal Subcutaneous fat area Abdominal Total fat area Body Mass Index (BMI)—

Countries

Japan

Contacts

Public ContactAkifumi Nagatomo

Morishita Jintan Co., Ltd. Health Care Product Department

a-nagatomo@jintan.co.jp072-800-1044

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026